Instanosis Inc. today announced that its Xylazine Rapid Test (Urine) has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA), representing a significant ...
Presently, a proposal is before CMS to drastically cut reimbursement for point-of-care test (POCT) devices used in urine drug screening. Outside interests are proposing these drastic cuts to CMS based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results